New agents and regimens for diffuse large B cell lymphoma

Table 3 Summary of antibody–drug conjugates and bispecific antibodies results in diffuse large B cell lymphoma

Target	Drug	Toxin	Combined agents	Study	Study phase	No.	Efficacy	References
CD19/CD3	Blinatumomab	–	R-chemotherapy	NCT 03023878	2	30	ORR 89%	[27]
CD19	Coltuximab ravtansine	DM4	–	NCT 01472887	2	61	ORR 44% CR 15%	[71]
CD19	Loncastuximab tesirine	SG3199	–	NCT 02669017	1	63	ORR 55% CR 37%	[72]
CD20	MT-3724	SLTA	–	NCT 02361346	1	13	ORR 30% CR 10%	[57]
CD20	Ibritumomab tiuxetan	Yttrium-90	Combined with R as maintenance therapy	NCT 00070018	2	33	5-y OS 87% 5-y PFS 82%	[59]
CD20	Tositumomab	Iodine-131	R-CHOP	NCT 00107380	2	86	ORR 86% CR 61% 2-yPFS69% 2-y OS 77%	[61]
CD20/CD3	RG6026	–	Obinutuzumab	NCT 03075696	1b	28	ORR 48% CR 43%	[30]
CD20/CD3	Mosunetuzumab	–	–	NCT 02500407	1/1b	55	ORR 33% CR 21%	[31]
CD20/CD3	REGN1979	–	–	NCT 02290951	1	53	ORR 33% CR 18%	[32]
CD22	Pinatuzumab vedotin	MMAE	Rituximab	NCT 01691898	2	42	ORR 60% CR 26%	[65]
CD22	Inotuzumab ozogamicin	Calicheamicin	Rituximab	NCT 00299494	1/2	42	ORR 74% 2-y EFS 42%	[76]
CD22	Epratuzumab tetraxetan	Yttrium-90	R-CHOP	NCT 00906841	2	71	2-y EFS 75%	[142]
CD30	Brentuximab vedotin	MMAE	–	NCT 02280785	2	12	CR 17% DCR 50%	[78]
CD30	Brentuximab vedotin	MMAE	–	NCT 01421667	2	49	ORR 44% CR 17% mPFS: 4 m	[80]
CD74	STRO-001	Maytansinoid warhead	–	NCT 03424603	1	4	ORR 50% CR 25%	[83]
CD79b	Polatuzumab vedotin	MMAE	Rituximab	NCT 01691898	2	39	ORR 54% CR 21% mDoR 13.4 m	[65]
CD79b	Polatuzumab vedotin	MMAE	R-CHP/GHP	NCT 01992653	1b/2	66	ORR 89% CR 77%	[64]

MMAE monomethyl auristatin E, AEs adverse events, NEs neurologic events, SLTA Shiga-like toxin-I A1, NHL non-Hodgkin lymphoma, CRS cytokine release syndrome, mDoR median duration of response, EFS event-free survival, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, ORR objective response rate, CR complete response, GHP obinutuzumab, doxorubicin, prednisone

ISSN: 1756-8722